Market capitalization | $2.34b |
Enterprise Value | $2.36b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 120.19 |
P/S ratio (TTM) P/S ratio | 118.87 |
P/B ratio (TTM) P/B ratio | 7.06 |
Revenue growth (TTM) Revenue growth | -92.33% |
Revenue (TTM) Revenue | $19.65m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
16 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:
16 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 20 20 |
92%
92%
|
|
Gross Profit | 2.22 2.22 |
99%
99%
|
|
EBITDA | -530 -530 |
213%
213%
|
EBIT (Operating Income) EBIT | -547 -547 |
203%
203%
|
Net Profit | -539 -539 |
197%
197%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Head office | United States |
CEO | Christopher Anzalone |
Employees | 525 |
Founded | 1989 |
Website | www.arrowheadpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.